The Practical and Mechanistic Role of Short-Acting GLP-1 Receptor Agonists for Managing PPG in Complex Patients Already on Basal Insulin: How Do Short-Acting GLP-1 RAs Optimize the Safety-Benefit Equation in Patients Requiring Pan-Glycemic Control?

The Practical and Mechanistic Role of Short-Acting GLP-1 Receptor Agonists for Managing PPG in Complex Patients Already on Basal Insulin: How Do Short-Acting GLP-1 RAs Optimize the Safety-Benefit Equation in Patients Requiring Pan-Glycemic Control?


Published

June 28, 2017

Created by

CMEducation Resources symposium

Related Presenters

Vivian Fonseca, FRCP, MD

Vivian Fonseca, FRCP, MD

Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
Past President, Science and Medicine American Diabetes Association (ADA)